← All trials
NCT06773507
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 12, 2025
- Primary completion
- Jun 30, 2026
- Completion date
- Jun 30, 2027
- First posted
- Jan 14, 2025
- Last posted
- Jul 9, 2025
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shaanxi Buchang Pharmaceutical Co., LtdLead sponsor
- Chinese Academy of Medical SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.